Abstract
In my view, the development of combination products should proceed concomitantly with the development of new chemical entities since, for the same investment, one can get two products marketed with the same effort. Current practice is to develop just the new chemical entity and, after it is marketed, doing a whole other set of trials that develop a combination product. There is a lot of room for improvement in combination product development.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Kluwer Academic Publishers, Boston
About this chapter
Cite this chapter
Lipicky, R.J. (1988). Combination Drug Therapy: What Studies are Required to Obtain Approval?. In: Morganroth, J., Moore, E.N. (eds) Silent Myocardial Ischemia. Developments in Cardiovascular Medicine, vol 88. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1745-6_14
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1745-6_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8980-7
Online ISBN: 978-1-4613-1745-6
eBook Packages: Springer Book Archive